Investors are more bullish on the company recently if you consider the downtick in short interest. The stock realized a fall in short interest of -19.96% as of the latest report on August 31, 2017. Short interest fell 22,011 over that timeframe. The short-interest ratio increased to 4.0 and the short interest percentage is 0.01% as of August 31.
Additionally, here are a few investment firms who have increased or decreased their stake in (PRTO). As of quarter end Kcg Holdings, Inc. had sold a total of 23,742 shares trimming its holdings by 64.8%. The value of the total investment in Proteon Therapeutics, Inc. decreased from $64,000 to $20,000 a change of $44,000 quarter over quarter. As of the end of the quarter Tower Research Capital LLC (trc) had disposed of 3,115 shares trimming its stake by 53.8%. The value in dollars went from $10,000 to $4,000 decreasing 60.0% for the reporting period.
As of the end of the quarter Mariner Wealth Advisors, LLC had disposed of a total of 1,125 shares trimming its position 10.1%. The value of the investment in Proteon Therapeutics, Inc. went from $19,000 to $15,000 a change of 21.1% since the last quarter. As of the end of the quarter Blackrock Inc. had sold a total of 22,265 shares trimming its holdings by 94.2%. The value of the investment in (PRTO) decreased from $41,000 to $2,000 decreasing 95.1% quarter to quarter.
The company is down by 9.37%% since yesterday’s close of 1.6. Shares are trading at $1.45 marginally over $1.36, the stock’s 50 day moving average and a tad higher than the 200 day moving average of $1.43. The 50 day moving average went up by +6.28% and the 200 day average went up $0.02 or +1.37%.
As of the latest earnings report the EPS was $-1.56 and is estimated to be $-1.52 for the current year with 17,619,000 shares currently outstanding. Analysts expect next quarter’s EPS to be $-0.41 with next year’s EPS projected to be $-1.54.
Proteon Therapeutics, Inc., launched on March 24, 2006, is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Business’s product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). It initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs..